Literature DB >> 10074928

Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells.

A Kraus1, F Neff, M Behn, M Schuermann, K Muenkel, J Schlegel.   

Abstract

A puzzling finding in various human tumors, including glioblastoma multiforme (GBM), is the stabilization of wild-type (wt) p53 protein. The biological significance of this phenomenon and the mechanism by which it occurs are unexplained. Recent reports have revealed that mdm2 exerts its negative regulation on the p53 signal by directly binding p53 protein and thereby instigating its proteasomal degradation. mdm2 has been shown to exist in alternatively spliced forms in human ovarian and bladder carcinomas, and recently in GBM, with loss or disruption of its p53 binding domain. Here we report that alternatively spliced transcripts of mdm2 are present in 7 of 16 human GBM primary cell cultures and in the established GBM cell lines LN 229 and LN 18. Sequencing demonstrated loss of the amino terminal p53 binding domain in these alternatively spliced mdm2 transcripts, and an out-of-frame splicing in the majority of cases. A significant correlation between the presence of mdm2 splice variants and increased expression of wt p53 protein was observed. Furthermore, in the presence of an mdm2 splice variant, wt p53 stabilization occurred despite coincident MDM2 amplification. Our findings suggest that wt p53 protein stabilization may arise as a consequence of alternative splicing of mdm2. Such a mechanism might account for wt p53 protein accumulation in GBM cells, even in the presence of MDM2 gene amplification.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074928     DOI: 10.1002/(sici)1097-0215(19990315)80:6<930::aid-ijc20>3.0.co;2-m

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma.

Authors:  Aishwarya G Jacob; Dennis O'Brien; Ravi K Singh; Daniel F Comiskey; Robert M Littleton; Fuad Mohammad; Jordan T Gladman; Maria C Widmann; Selvi C Jeyaraj; Cheryl Bolinger; James R Anderson; Donald A Barkauskas; Kathleen Boris-Lawrie; Dawn S Chandler
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

2.  The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA.

Authors:  Aishwarya G Jacob; Ravi K Singh; Fuad Mohammad; Thomas W Bebee; Dawn S Chandler
Journal:  J Biol Chem       Date:  2014-05-05       Impact factor: 5.157

3.  P53 gene mutation and expression of MDM2, P53, P16 protein and their relationship in human glioma.

Authors:  Wen Cui; Renliang Wu; Huiling Cao; Jifa Gao; Xu Wang; Qiwei Ren
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

4.  A small nuclear RNA, hdm365, is the major processing product of the human mdm2 gene.

Authors:  S Bartl; J Ban; H Weninger; G Jug; H Kovar
Journal:  Nucleic Acids Res       Date:  2003-02-15       Impact factor: 16.971

5.  Splicing up mdm2 for cancer proteome diversity.

Authors:  Danielle R Okoro; Melissa Rosso; Jill Bargonetti
Journal:  Genes Cancer       Date:  2012-03

6.  The ubiquitin-proteasome system in glioma cell cycle control.

Authors:  Panagiotis J Vlachostergios; Ioannis A Voutsadakis; Christos N Papandreou
Journal:  Cell Div       Date:  2012-07-20       Impact factor: 5.130

7.  Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage.

Authors:  Daniel F Comiskey; Aishwarya G Jacob; Ravi K Singh; Aixa S Tapia-Santos; Dawn S Chandler
Journal:  Nucleic Acids Res       Date:  2015-04-06       Impact factor: 16.971

8.  Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways.

Authors:  Aishwarya G Jacob; Ravi K Singh; Daniel F Comiskey; Matthew F Rouhier; Fuad Mohammad; Thomas W Bebee; Dawn S Chandler
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

9.  Identification of mRNA isoform switching in breast cancer.

Authors:  Wei Zhao; Katherine A Hoadley; Joel S Parker; Charles M Perou
Journal:  BMC Genomics       Date:  2016-03-03       Impact factor: 3.969

10.  A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.

Authors:  D F Comiskey; A G Jacob; B L Sanford; M Montes; A K Goodwin; H Steiner; E Matsa; A S Tapia-Santos; T W Bebee; J Grieves; K La Perle; P Boyaka; D S Chandler
Journal:  Oncogene       Date:  2017-09-11       Impact factor: 9.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.